Bristol Myers Squibb (NYSE: BMY) reported its third quarter 2025 earnings results today. Revenues increased 3% year-over-year to $12.2 billion. GAAP net income attributable to Bristol Myers Squibb was $2.2 billion, or $1.08 per share, compared to $1.2 billion, or $0.60 per share, last year. Adjusted EPS was $1.63, down 9% YoY. For full-year 2025, […]
Bristol Myers Squibb (NYSE: BMY) reported its third quarter 2025 earnings results today. Revenues increased 3% year-over-year to $12.2 billion. GAAP net income attributable to Bristol Myers Squibb was $2.2 billion, or $1.08 per share, compared to $1.2 billion, or $0.60 per share, last year. Adjusted EPS was $1.63, down 9% YoY. For full-year 2025, […]
Bristol Myers Squibb (NYSE: BMY) reported its third quarter 2025 earnings results today.
Revenues increased 3% year-over-year to $12.2 billion.
GAAP net income attributable to Bristol Myers Squibb was $2.2 billion, or $1.08 per share, compared to $1.2 billion, or $0.60 per share, last year. Adjusted EPS was $1.63, down 9% YoY.
For full-year 2025, revenue is expected to be $47.5-48.0 billion. Adjusted EPS is expected to be $6.40-6.60.
